Lyu T, Zhang Y. Targeting leukemia stem cells in unfit acute myeloid leukemia with a CD70-directed third agent: promise and caveats from the ELEVATE trial. Comment on: “Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study”. haematol [Internet]. 2020Sep.10 [cited 2026Oct.13];. Available from: https://haematologica.org/article/view/haematol.2026.302003